Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + SBRT in Inoperable Stage I NSCLC
NCT02599454Phase 1Completed
- Start
- Apr 2018
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atezolizumab in non-small cell lung cancer (NSCLC). Primary endpoint: Maximum Tolerated Dose at 9 weeks. Started Apr 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02599454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02599454.